Novartis, Pfizer join forces on potentially lucrative fatty liver disease

Novartis, Pfizer join forces on potentially lucrative fatty liver disease - Hallo friend NEWS AN INSPIRATION, In the article you read this time with the title Novartis, Pfizer join forces on potentially lucrative fatty liver disease, we have prepared well for this article you read and download the information therein. hopefully fill posts Article ECONOMY, Article HEALTH, Article POLITICS, Article SPORTS, Article TRAVELING, Article UPDATE, we write can understand. Well, happy reading.

Titre : Novartis, Pfizer join forces on potentially lucrative fatty liver disease
link : Novartis, Pfizer join forces on potentially lucrative fatty liver disease

Read also


Novartis, Pfizer join forces on potentially lucrative fatty liver disease

Novartis, Pfizer join forces on potentially lucrative fatty liver disease
John Miller, Michael Erman

ZURICH/NEW YORK (Reuters) - Novartis AG and Pfizer Inc are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market, as it is tied to the obesity and diabetes epidemics.

The Swiss and U.S. drugmakers announced on Monday that they will collaborate to develop combination therapies involving medicines they have been working on separately to treat nonalcoholic steatohepatitis, or NASH.

Though hardly a household name, the progressive fatty liver disease with no approved treatments is poised to become the leading cause of liver transplants by 2020. 



Thus articles Novartis, Pfizer join forces on potentially lucrative fatty liver disease

that is all articles Novartis, Pfizer join forces on potentially lucrative fatty liver disease This time, hopefully can provide benefits to you all. Okay, see you in another article post.

You are now reading the article Novartis, Pfizer join forces on potentially lucrative fatty liver disease the link address https://newsaninpiration.blogspot.com/2018/10/novartis-pfizer-join-forces-on.html

Subscribe to receive free email updates:

Related Posts :

0 Response to "Novartis, Pfizer join forces on potentially lucrative fatty liver disease"

Post a Comment